Management of spinal hemangioblastoma

Management of spinal hemangioblastoma - MOSH

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033224

Enrollment

200

Registered

2023-12-11

Start date

2024-01-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D33.4

Interventions

Group 1: Evaluation of clinical and imaging data of patients treated for spinal hemangioblastoma from January 1980 to December 2023.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult patients treated for spinal hemangioblastoma from January 1980 to December 2023.

Exclusion criteria

Exclusion criteria: Patient age <18 years at the time of treatment of spinal hemangioblastoma. Data not analyzable.

Design outcomes

Primary

Measure	Time frame
Assessment of medical findings and therapeutic interventions in the treatment of spinal hemangioblastomas	—

Secondary

Measure	Time frame
Intraoperative/postoperative complications, duration of surgery, clinical-neurological follow-up	—

Countries

Germany

Contacts

Public ContactJan-Helge Klingler

Universitätsklinikum Freiburg

jan-helge.klingler@uniklinik-freiburg.de076127050010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026